Assessment of the anti-anaemic activity of a ready-to-serve beverage developed from sharbat-e-gudhal (a traditional hibiscus rosa-sinensis syrup) in comparison with traditional sharbat-e-gudhal and ferrous sulphate supplementation in patients with mild iron-deficiency anaemia

ISRCTN ISRCTN16279156
DOI https://doi.org/10.1186/ISRCTN16279156
Sponsor University of Sri Jayewardenepura
Funder Investigator initiated and funded
Submission date
03/07/2026
Registration date
08/07/2026
Last edited
15/09/2026
Recruitment status
Recruiting
Overall study status
Ongoing
Condition category
Haematological Disorders
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Fathima Rizniya
Principal investigator, Scientific, Public

No. 50 St. Lazarus Road, Periyamulla
Negombo
11500
Sri Lanka

ORCiD logoORCID ID 0009-0001-0963-2528
Phone +94 (0)773016949
Email rizniyamnf@fim.cmb.ac.lk
Prof Bernadene Fernandopulle
Scientific

Department of Pathology, Faculty of Medical Sciences, University of Sri Jayewardenepura
Sri Jayewardenepura
10100
Sri Lanka

ORCiD logoORCID ID 0000-0002-0024-5054
Phone +94 (0)777746864
Email fernandopulle@sjp.ac.lk
Prof Pradeepa Jayawardane
Scientific

Department of Pharmacology, University of Sri Jayewardenepura
Sri Jayewardenepura
10100
Sri Lanka

ORCiD logoORCID ID 0009-0004-8937-1488
Phone +94 (0)712304322
Email pradeepa@sjp.ac.lk
Prof Kamal Perera
Scientific

Faculty of Indigenous Medicine, University of Colombo, Rajagiriya
Sri Jayewardanapura
10100
Sri Lanka

ORCiD logoORCID ID 0000-0003-0337-1336
Email kamalperea@fim.cmb.ac.lk
Dr Mohamed Mawjood
Public, Scientific

Faculty of Indigenous Medicine, University of Colombo, Rajagiriya
Sri Jayewardanapura
10100
Sri Lanka

Phone +94 (0)714422394
Email drmawjood@fim.cmb.ac.lk

Study information

Primary study designInterventional
AllocationRandomized controlled trial
MaskingOpen (masking not used)
ControlActive
AssignmentParallel
PurposeTreatment
Scientific titleEfficacy and safety of a ready-to-serve beverage derived from sharbat-e-gudhal (a traditional syrup of China rose-unani formula used in faqrud dam [anemia]) in the management of mild iron-deficiency anaemia: a randomized controlled trial
Study objectives To comparatively evaluate efficacy and safety of a ready-to-serve (RTS) beverage derived from sharbat e gudhal and sharbat e gudhal (the traditional syrup) with standard iron supplements in patients with mild iron deficiency anaemia.
Ethics approval(s)

Approved 29/04/2026, Ethical Review Committee, Faculty of Indigenous Medicine (University of Colombo, Rajagiriya, Colombo, 10100, Sri Lanka; +94 (0)112692385; ethicsreview@fim.cmb.ac.lk), ref: ERC 24/265

Health condition(s) or problem(s) studiedAnaemia
InterventionRecruited patients will be asked to visit the clinic periodically as the instructions given by the principal investigator (3 weeks after the first visit, with completion of the first month and monthly thereafter). Participants will be assigned to test groups I and II and the control group as described below.
Group I: 150 ml of RTS beverage from sharbat-e-gudhal given at 10:00 am as a snack
Group II: Sharbat-e-gudhal given as 25 ml in the morning and 25 ml at night before meals
Control group: one tablet of ferrous sulphate (200 mg) with one tablet of vitamin C (100 mg) at night 2 hours before dinner

Randomization will be done using computer-generated random numbers that are obtained using Research Randomizer.

Duration of protocol therapy: 120 days

The patients will be assessed subjectively and by objective parameters on days 0 (baseline), 21, 90, and 120. On these days a questionnaire will be administered to them by the investigators to collect data on their views regarding the improvement of symptoms on treatment and to detect any adverse effects of the treatment. Further, a blood sample (5 ml) will be taken for the required analysis by a qualified phlebotomist (nurse/medical lab technician). The blood tests will be performed at an accredited laboratory
Intervention typeDrug
PhasePhase II
Drug / device / biological / vaccine name(s)RTs beverage derived from sharbat-e-gudhal
Primary outcome measure(s)
  1. Haemoglobin levels measured using fully automated haematology analyzer at baseline, 21st , 90th and 120th days
  2. Serum ferritin levels measured using a specialized immunoassay analyzer at baseline and 120th day
Key secondary outcome measure(s)

1. Liver function (serum glutamic oxaloacetic transaminase [SGOT], serum glutamic-pyruvic transaminase [SGPT] and serum bilirubin levels) measured using the automated biochemistry analyzer at baseline, 21st, 90th and 120th days
2. Kidney function (serum creatinine levels) measured using the automated biochemistry analyzer at baseline, 21st, 90th and 120th days
3. Blood glucose control (glycated haemoglobin [HbA1c] levels) measured using the high-performance liquid chromatography (HPLC) at baseline and 90th day

Completion date14/03/2028

Eligibility

Participant type(s)
Age groupMixed
Lower age limit18 Years
Upper age limit65 Years
SexAll
Target sample size at registration114
Key inclusion criteria1. Mild anaemic patients
2. Either sex
3. Aged 18 to 65 years
4. Patients with confirmed mild iron deficiency anaemia with the following limits:
4.1. Hb%: female: ≥9 g/dl and ≤12 g/dl; male: ≥9 g/dl and ≤13 g/dl
4.2. Serum ferritin: ≤30 µg/l
Key exclusion criteria1. Patients below 18 years and above 65 years of age
2. Moderate to severe anaemia (Hb%: ≤9 g/dl)
3. Patient with concurrent respiratory diseases, cardiovascular diseases, liver diseases and renal diseases
4. Pregnant and lactating women
5. Patients with a history of diabetes mellitus
Date of first enrolment10/09/2026
Date of final enrolment31/10/2027

Locations

Countries of recruitment

  • Sri Lanka

Study participating centre

National Ayurveda Hospital
National Ayurveda Hospital, Borella
Colombo
Sri Lanka

Results and Publications

Individual participant data (IPD) Intention to shareYes
IPD sharing planThe datasets generated during and/or analysed during the current study are/will be available upon request from Dr MNF Rizniya (rizniyamnf@fim.cmb.ac.lk). Study participant data sheets will not include contact or identifying details. Study data entry and study management systems used by clinical sites will be secured and password protected. At the end of the study, all study databases will be de-identified and archived. Availability of raw data of the study is based on the above conditions.

Editorial Notes

15/09/2026: The date of first enrolment was changed from 01/08/2026 to 10/09/2026.
13/07/2026: Contact details updated.
03/07/2026: Study's existence confirmed by the University of Sri Jayewardenepura.